Multivariate analysis of association of clinical and biologic characteristics with outcome
Variable . | Genotype . | P . | RR (95% CI) . |
|---|---|---|---|
| Patients with intermediate-risk AML* | |||
| Chemoresistance | |||
| XPA | GG | .02 | 14 (2-23) |
| Overall survival | |||
| XPA | GG | .02 | 3.4 (2-9.4) |
| WBC count greater than 20,000 | — | .02 | 2.1 (1.1-4.1) |
| MDR1 (1) | TC/CC | .02 | 2.1 (1.1-4.1) |
| Relapse | |||
| SULT1C | CC/GG | 0.004 | 4.1 (1.6-10.7) |
| FLT3-ITD | — | 0.003 | 3.3 (1.5-7.3) |
| MDR1 (1) | TC/CC | 0.02 | 2.4 (1.1-5.4) |
| Patients with normal cytogenetics† | |||
| Chemoresistance | |||
| XPA | GG | .01 | 66 (2.3-193) |
| Overall survival | |||
| XPA | GG | .02 | 4 (1.1-13) |
| WBC count greater than 20,000 | — | < .001 | 2.6 (1.2-5.4) |
Variable . | Genotype . | P . | RR (95% CI) . |
|---|---|---|---|
| Patients with intermediate-risk AML* | |||
| Chemoresistance | |||
| XPA | GG | .02 | 14 (2-23) |
| Overall survival | |||
| XPA | GG | .02 | 3.4 (2-9.4) |
| WBC count greater than 20,000 | — | .02 | 2.1 (1.1-4.1) |
| MDR1 (1) | TC/CC | .02 | 2.1 (1.1-4.1) |
| Relapse | |||
| SULT1C | CC/GG | 0.004 | 4.1 (1.6-10.7) |
| FLT3-ITD | — | 0.003 | 3.3 (1.5-7.3) |
| MDR1 (1) | TC/CC | 0.02 | 2.4 (1.1-5.4) |
| Patients with normal cytogenetics† | |||
| Chemoresistance | |||
| XPA | GG | .01 | 66 (2.3-193) |
| Overall survival | |||
| XPA | GG | .02 | 4 (1.1-13) |
| WBC count greater than 20,000 | — | < .001 | 2.6 (1.2-5.4) |